Skip to main content
Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: The translational potential of miR-26 in atherosclerosis and development of agents for its target genes ACC1/2, COL1A1, CPT1A, FBP1, DGAT2, and SMAD7

Fig. 3

MiR-26 delivery systems and targeting ACC1/2, CT-1, DGAT2, and PCSK9 with drugs that were approved or investigated in clinical trials. ADSCs overexpressing miR-26 reduced IMT more than those with PCSK9 or CT-1 knockout. DGAT2 inhibitors can reduce the side effects of ACC1/2 inhibitors. Multiple materials have been used to deliver miR-26. ACC1 acetyl-CoA-carboxylase 1, CT-1 cardiotrophin-1, PCSK9 Proprotein convertase subtilisin/kexin type 9

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840